信迪利单抗联合XELOX方案治疗晚期胃癌的近期疗效及安全性分析

Analysis of Short-term Efficacy and Safety of Sintilimab Combined with XELOX Regimen in the Treatment of Advanced Gastric Cancer

目的探究信迪利单抗联合XELOX方案(奥沙利铂+卡培他滨)治疗晚期胃癌的近期疗效及安全性。方法选取2022年1月-2023年8月安福县人民医院收治的晚期胃癌患者60例作为研究对象,按照随机数字表法分为研究组和对照组,各30例。对照组采用XELOX方案治疗,研究组采用信迪利单抗联合XELOX方案治疗。比较两组治疗后临床疗效、不良反应发生率、肿瘤标志物水平[甲胎蛋白(AFP)、糖类抗原153(CA153)、糖类抗原724(CA724)、癌胚抗原(CEA)、糖类抗原125(CA125)及糖链抗原19-9(CA19-9)]。结果研究组临床治疗有效率高于对照组,不良反应发生率低于对照组(P<0.05);两组治疗后AFP、CA153、CA724、CEA、CA125、CA19-9水平低于治疗前,且研究组AFP、CA153、CA724、CEA、CA125、CA19-9水平低于对照组(P<0.05)。结论信迪利单抗联合XELOX方案治疗晚期胃癌的效果良好,有助于降低血清肿瘤标记物水平及不良反应发生率,值得临床应用。

Objective To investigate the short-term efficacy and safety of sintilimab combined with XELOX regimen(oxaliplatin+capecitabine)in the treatment of advanced gastric cancer.Methods A total of 60 patients with advanced gastric cancer admitted to Anfu County People's Hospital from January 2022 to August 2023 were selected as the research objects.According to the random number table method,they were divided into study group and control group,with 30 patients in each group.The control group was treated with XELOX regimen,and the study group was treated with sintilimab combined with XELOX regimen.The clinical efficacy,incidence of adverse reactions and levels of tumor markers[alpha-fetoprotein(AFP),carbohydrate antigen 153(CA153),carbohydrate antigen 724(CA724),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 19-9(CA19-9)]were compared between the two groups after treatment.Results The effective rate of clinical treatment in the study group was higher than that in the control group,and the incidence of adverse reactions was lower than that in the control group(P<0.05).After treatment,the levels of AFP,CA153,CA724,CEA,CA125 and CA19-9 in the two groups were lower than those before treatment,and the levels of AFP,CA153,CA724,CEA,CA125 and CA19-9 in the study group were lower than those in the control group(P<0.05).Conclusion Sindilimab combined with XELOX regimen is effective in the treatment of advanced gastric cancer,which is helpful to reduce the level of serum tumor markers and the incidence of adverse reactions.It is worthy of clinical application.